Aerie Pharma (AERI) Tops Q3 EPS by 10c

Aerie Pharma (NASDAQ: AERI) reported Q3 EPS of ($0.56), $0.10 better than the analyst estimate of ($0.66).

As of September 30, 2015, Aerie had cash, cash equivalents and investments of $162.9 million, consistent with the prior quarter’s as the result of sales made under our “at-the-market” program, a component of the shelf registration statement filed in November of 2014.

“We are very pleased with the progress of our ongoing discussions with the FDA, and are now actively preparing for what promises to be a very important step in Aerie’s advancement, the filing of our NDA for once-daily RhopressaTM in the third quarter of next year. Additionally, we are experiencing a high degree of physician interest in our Mercury 1 and Rocket 4 trials, and expect 90-day efficacy results for each trial approximately a year from now,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer. “Additionally, our recently announced research collaborations with GrayBug for drug delivery technology and Ramot for their preclinical anti-beta amyloid small molecule product candidate are progressing very well.”

Dr. Anido continued, “We look forward to our investor and media event at noon Pacific Time on November 13, 2015, during the American Academy of Ophthalmology meeting in Las Vegas. At the meeting, we plan to cover further details on our Phase 3 clinical trial results for RhopressaTM, including a deeper dive into Rocket 2 results and regulatory considerations, along with updates on RoclatanTM and our preclinical research programs.”

For earnings history and earnings-related data on Aerie Pharma (AERI) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
• Innovative Solutions & Support (ISSC) Tops Q3 EPS by 10c